Vimentin as a poor prognostic factor for triple-negative breast cancer

Nami Yamashita, Eriko Tokunaga, Hiroyuki Kitao, Yuichi Hisamatsu, Kenji Taketani, Sayuri Akiyoshi, Satoko Okada, Shinichi Aishima, Masaru Morita, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

59 引用 (Scopus)

抄録

Purpose: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is a highly heterogeneous disease. Recent studies suggest that there are links between TNBC and the epithelial-mesenchymal transition (EMT). To identify prognostic biomarkers and novel therapeutic targets, vimentin, one of the most major factors associated with EMT was investigated in TNBC. Materials and methods: Sporadic invasive ductal carcinoma specimens were obtained from 659 Japanese patients, and 90 (14 %) cases were diagnosed as TNBC. The vimentin mRNA and protein expression levels were evaluated by quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Results: The mRNA expression of vimentin was significantly upregulated in the basal-type breast cancer cell line. Immunohistochemically, the vimentin expression was significantly higher (p = 0.0042) in TNBC compared with the other subtypes. Vimentin expression was associated with a younger age (p = 0.016), high nuclear grade (p = 0.023) and high Ki67 expression (p < 0.0001), and a poorer prognosis in terms of both the recurrence-free survival (RFS) (p = 0.0058) and overall survival (OS) (p = 0.013) in TNBC patients. A multivariate analysis showed that vimentin expression was an independent prognostic factor for the RFS (p = 0.043). Vimentin expression was also associated with a significantly shorter RFS (p = 0.021) and OS (p = 0.017) in patients with basal-like breast cancer (BLBC). Conclusions: The elevated expression of vimentin contributes to the aggressive phenotype and poor prognosis in TNBC. Vimentin expression might be useful as a biomarker for the prognosis of TNBC.

元の言語英語
ページ(範囲)739-746
ページ数8
ジャーナルJournal of Cancer Research and Clinical Oncology
139
発行部数5
DOI
出版物ステータス出版済み - 5 1 2013

Fingerprint

Triple Negative Breast Neoplasms
Vimentin
Survival
Epithelial-Mesenchymal Transition
Recurrence
Biomarkers
Breast Neoplasms
Ductal Carcinoma
Messenger RNA
Progesterone Receptors
Reverse Transcriptase Polymerase Chain Reaction
Estrogen Receptors
Multivariate Analysis
Immunohistochemistry
Phenotype
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Vimentin as a poor prognostic factor for triple-negative breast cancer. / Yamashita, Nami; Tokunaga, Eriko; Kitao, Hiroyuki; Hisamatsu, Yuichi; Taketani, Kenji; Akiyoshi, Sayuri; Okada, Satoko; Aishima, Shinichi; Morita, Masaru; Maehara, Yoshihiko.

:: Journal of Cancer Research and Clinical Oncology, 巻 139, 番号 5, 01.05.2013, p. 739-746.

研究成果: ジャーナルへの寄稿記事

Yamashita, N, Tokunaga, E, Kitao, H, Hisamatsu, Y, Taketani, K, Akiyoshi, S, Okada, S, Aishima, S, Morita, M & Maehara, Y 2013, 'Vimentin as a poor prognostic factor for triple-negative breast cancer', Journal of Cancer Research and Clinical Oncology, 巻. 139, 番号 5, pp. 739-746. https://doi.org/10.1007/s00432-013-1376-6
Yamashita, Nami ; Tokunaga, Eriko ; Kitao, Hiroyuki ; Hisamatsu, Yuichi ; Taketani, Kenji ; Akiyoshi, Sayuri ; Okada, Satoko ; Aishima, Shinichi ; Morita, Masaru ; Maehara, Yoshihiko. / Vimentin as a poor prognostic factor for triple-negative breast cancer. :: Journal of Cancer Research and Clinical Oncology. 2013 ; 巻 139, 番号 5. pp. 739-746.
@article{2d0ed0cc58de4f75b7f405e5f1611c13,
title = "Vimentin as a poor prognostic factor for triple-negative breast cancer",
abstract = "Purpose: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is a highly heterogeneous disease. Recent studies suggest that there are links between TNBC and the epithelial-mesenchymal transition (EMT). To identify prognostic biomarkers and novel therapeutic targets, vimentin, one of the most major factors associated with EMT was investigated in TNBC. Materials and methods: Sporadic invasive ductal carcinoma specimens were obtained from 659 Japanese patients, and 90 (14 {\%}) cases were diagnosed as TNBC. The vimentin mRNA and protein expression levels were evaluated by quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Results: The mRNA expression of vimentin was significantly upregulated in the basal-type breast cancer cell line. Immunohistochemically, the vimentin expression was significantly higher (p = 0.0042) in TNBC compared with the other subtypes. Vimentin expression was associated with a younger age (p = 0.016), high nuclear grade (p = 0.023) and high Ki67 expression (p < 0.0001), and a poorer prognosis in terms of both the recurrence-free survival (RFS) (p = 0.0058) and overall survival (OS) (p = 0.013) in TNBC patients. A multivariate analysis showed that vimentin expression was an independent prognostic factor for the RFS (p = 0.043). Vimentin expression was also associated with a significantly shorter RFS (p = 0.021) and OS (p = 0.017) in patients with basal-like breast cancer (BLBC). Conclusions: The elevated expression of vimentin contributes to the aggressive phenotype and poor prognosis in TNBC. Vimentin expression might be useful as a biomarker for the prognosis of TNBC.",
author = "Nami Yamashita and Eriko Tokunaga and Hiroyuki Kitao and Yuichi Hisamatsu and Kenji Taketani and Sayuri Akiyoshi and Satoko Okada and Shinichi Aishima and Masaru Morita and Yoshihiko Maehara",
year = "2013",
month = "5",
day = "1",
doi = "10.1007/s00432-013-1376-6",
language = "English",
volume = "139",
pages = "739--746",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Vimentin as a poor prognostic factor for triple-negative breast cancer

AU - Yamashita, Nami

AU - Tokunaga, Eriko

AU - Kitao, Hiroyuki

AU - Hisamatsu, Yuichi

AU - Taketani, Kenji

AU - Akiyoshi, Sayuri

AU - Okada, Satoko

AU - Aishima, Shinichi

AU - Morita, Masaru

AU - Maehara, Yoshihiko

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Purpose: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is a highly heterogeneous disease. Recent studies suggest that there are links between TNBC and the epithelial-mesenchymal transition (EMT). To identify prognostic biomarkers and novel therapeutic targets, vimentin, one of the most major factors associated with EMT was investigated in TNBC. Materials and methods: Sporadic invasive ductal carcinoma specimens were obtained from 659 Japanese patients, and 90 (14 %) cases were diagnosed as TNBC. The vimentin mRNA and protein expression levels were evaluated by quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Results: The mRNA expression of vimentin was significantly upregulated in the basal-type breast cancer cell line. Immunohistochemically, the vimentin expression was significantly higher (p = 0.0042) in TNBC compared with the other subtypes. Vimentin expression was associated with a younger age (p = 0.016), high nuclear grade (p = 0.023) and high Ki67 expression (p < 0.0001), and a poorer prognosis in terms of both the recurrence-free survival (RFS) (p = 0.0058) and overall survival (OS) (p = 0.013) in TNBC patients. A multivariate analysis showed that vimentin expression was an independent prognostic factor for the RFS (p = 0.043). Vimentin expression was also associated with a significantly shorter RFS (p = 0.021) and OS (p = 0.017) in patients with basal-like breast cancer (BLBC). Conclusions: The elevated expression of vimentin contributes to the aggressive phenotype and poor prognosis in TNBC. Vimentin expression might be useful as a biomarker for the prognosis of TNBC.

AB - Purpose: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is a highly heterogeneous disease. Recent studies suggest that there are links between TNBC and the epithelial-mesenchymal transition (EMT). To identify prognostic biomarkers and novel therapeutic targets, vimentin, one of the most major factors associated with EMT was investigated in TNBC. Materials and methods: Sporadic invasive ductal carcinoma specimens were obtained from 659 Japanese patients, and 90 (14 %) cases were diagnosed as TNBC. The vimentin mRNA and protein expression levels were evaluated by quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Results: The mRNA expression of vimentin was significantly upregulated in the basal-type breast cancer cell line. Immunohistochemically, the vimentin expression was significantly higher (p = 0.0042) in TNBC compared with the other subtypes. Vimentin expression was associated with a younger age (p = 0.016), high nuclear grade (p = 0.023) and high Ki67 expression (p < 0.0001), and a poorer prognosis in terms of both the recurrence-free survival (RFS) (p = 0.0058) and overall survival (OS) (p = 0.013) in TNBC patients. A multivariate analysis showed that vimentin expression was an independent prognostic factor for the RFS (p = 0.043). Vimentin expression was also associated with a significantly shorter RFS (p = 0.021) and OS (p = 0.017) in patients with basal-like breast cancer (BLBC). Conclusions: The elevated expression of vimentin contributes to the aggressive phenotype and poor prognosis in TNBC. Vimentin expression might be useful as a biomarker for the prognosis of TNBC.

UR - http://www.scopus.com/inward/record.url?scp=84876295683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876295683&partnerID=8YFLogxK

U2 - 10.1007/s00432-013-1376-6

DO - 10.1007/s00432-013-1376-6

M3 - Article

C2 - 23354842

AN - SCOPUS:84876295683

VL - 139

SP - 739

EP - 746

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 5

ER -